Eton Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Eton Pharmaceuticals, Inc. - overview
Established
2017
Location
Deer Park, IL, US
Primary Industry
Pharmaceuticals
About
Based in Illinois, US, and founded in 2017, Eton Pharmaceuticals, Inc. , also known as Eton, operates as a pharmaceutical company. The company is a spin-out company of Imprimis Pharmaceuticals, Inc. , and it was founded by Mark Baum.
In October 2020, Eton Pharmaceuticals, Inc. raised USD 19. 60 million in a private placement, selling 2. 80 million shares at USD 7 per share.
In June 2022, Dr. Reddy's Laboratories Ltd acquired Eton Pharmaceuticals, Inc's branded and generic injectable products portfolio from Eton Pharmaceuticals, Inc for USD 50 million. As of 2022, the company’s CEO is Sean Brynjelsen, and it has 17 employees. The company trades on NASDAQ under the ticker symbol ETON.
Eton develops various pharmaceutical products for treating rare diseases. The products marketed by the company include Alkindi Sprinkle (hydrocortisone oral granules), Carglumic Acid, which is a medicine to treat and prevent hyperammonemia (excessive blood levels of ammonia) in patients, Biorphen (phenylephrine hydrochloride), which is an alpha-1 adrenergic receptor agonist, Eprontia, which is a prescription drug used to treat some forms of seizures and avoid migraines, and Alaway, which is an eye drop that is used to treat itching of the eyes. The company generated a revenue of USD 3. 2 million for the 3rd quarter of 2022, with a profit of USD 2.
0 million.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.etonpharma.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Eton Pharmaceuticals, Inc. - timeline of key events
Eton Pharmaceuticals, Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 959,000 | 39,000 | 21,832,000 | 21,251,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | (95.9%) | 55879.5% | (2.7%) | - | - | - |
| EBITDA (USD) | (10,258,000) | (18,138,000) | (26,339,000) | (885,000) | (6,359,000) | - | - | - |
| Operating Income (USD) | (10,321,000) | (18,601,000) | (27,111,000) | (1,495,000) | (8,260,000) | - | - | - |
| Operating Margin | - | (1939.6%) | (69515.4%) | (6.8%) | (38.9%) | - | - | - |
| % EBITDA Margin | - | (1891.3%) | (67535.9%) | (4.1%) | (29.9%) | - | - | - |
| NET Income (USD) | (12,740,000) | (18,320,000) | (27,970,000) | (1,955,000) | (9,021,000) | - | - | - |
| % Net Margin | - | (1910.3%) | (71717.9%) | (9.0%) | (42.4%) | - | - | - |
Eton Pharmaceuticals, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.